For patients with advanced melanoma without BRAF mutation who no longer respond to immune checkpoint inhibitors, treatment ...

A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and identifies a new combination treatment. Publishing in Nature Immunology, ...

In a study published in the journal Biofunctional materials, researchers from the Wits Advanced Drug Delivery Platform (WADDP) Research Unit, Department of Pharmacy and Pharmacology, and the Division ...

For many people diagnosed with cancer, treatment with immune checkpoint inhibitors (ICIs) has dramatically extended lives. Some of these treatments, such as Keytruda and Opdivo, have become familiar ...

Researchers have shown HIF1α as a key regulator that induces the cancer-killing capacity of T cells in hypoxic conditions. A team of researchers from the University of Alabama at Birmingham (AL, USA) ...

A phase 2 trial showed that combining targeted radiotherapy with PD-1 blockade and a bevacizumab biosimilar can elicit responses in advanced liver cancer.

Adding a second checkpoint inhibitor to chemotherapy improves outcomes among patients with non–small cell lung cancer (NSCLC) who have STK11 and/or KEAP1 mutations, according to the authors of a new ...

Immune system activation and activity is regulated through stimulatory or inhibitory ligand-receptor interactions collectively termed immune checkpoints. 1 Stimulatory interactions give the immune ...

A research team from the National Center for Nanoscience and Technology of the Chinese Academy of Sciences, in collaboration with Chongqing Medical University, has developed three types of ...

Adding an immune checkpoint inhibitor to standard Bacillus Calmette-Guérin (BCG) therapy for non–muscle invasive bladder cancer (NMIBC) might reduce recurrences in a small fraction of patients, but ...